Empowering Innovation in Life Sciences: Bridging Ideas with Impact

Driven By Our vision, Grounded in Our Mission

Our Vision

To redefine what’s possible in life science innovation. We empower trailblazing innovators to transform healthcare, advancing access, improving lives, and accelerating the journey from discovery to impact.

Our Mission

Accelerate the path to market for clinically impactful life science solutions. We equip innovators with the expertise, resources, and capital needed to improve patient outcomes, reduce time to impact, and drive sustainable growth.

Built to Move Innovation Forward Our Role in the Innovation Ecosystem

Our Beginning

Founded in 2017, LifeX® was created as the landing spot for high-potential technologies emerging from universities-helping founders move from discovery to scalable companies.

Where We Operate

Rooted in Pittsburgh, nationally connected.
We support startups across Pennsylvania and beyond, while strengthening Pittsburgh as a leading hub for life science innovation.

Our Commitment

Designated as a Pennsylvania Life Sciences Greenhouse in 2022, LifeX plays a key role in advancing early-stage innovation, job creation, and regional economic growth.

The LifeX Platform

Rooted in Entrepreneurial Spirit

Like most entrepreneurs, the LifeX story begins with a problem: navigating the path from life science innovation to commercial success requires vast networks, business expertise, commercial insight, and capital. It’s a journey too complex for founders to take on alone.

Over the past decade, early-stage life science investment has undergone a structural shift. Venture activity in life sciences has steadily declined in recent years, with the concentration of capital becoming increasingly focused on the geographic centers on the east and west coasts illustrating the resulting funding gap faced by underserved regions like Pennsylvania.

Over the Past Decade Early-Stage Life Science Investment Has Undergone a Structural Shift

Increased Focus on Later Stages
Life Science VCs are increasingly focusing on later-stage opportunities. Early stage companies are now expected to advance further, reduce technical and regulatory risk, and demonstrate greater capital efficiency before securing investment.
Seed Deal Volume Declines
In 2023 and 2024, first-round (pre-seed/seed) deal volume, fell dramatically below pre-COVID levels, with projections indicating that 2025 may be the worst year yet. This contraction signals a fundamental shift in venture behavior: life science venture capital is becoming increasingly selective, especially when it comes to early-stage startups.
Longer Gaps Between Rounds
Time between venture rounds has also steadily increased since 2021 leading founders to raising larger investment rounds that have clear and defined milestones to incentivize investors to invest. This has been a struggle for early-stage companies to solidify a strong strategic plan and investment round that will attract investors as well as give start-ups the needed runway to allow for adequate time to reach an inflection point and receive follow-on investment.

Life Science investment is showing a clear decline in deal volume, time between deals, and favoring larger round sizes. This focus can be attributed to investors becoming more risk averse with key areas of risk cited, including potential regulatory hurdles, evidence of compelling clinical data and validation, clarity around commercial opportunity, and market need validation.

Our Core Elements Work in Tandem to Equip Startups with the Essential Support Needed to Turn Scientific Innovation into Market Success

Active Engagement

With each month that passes without investment, a company's probability of success declines. That’s why we actively engage with founders to understand their unique needs and ensure every step, from mentorship to programming, is aligned for growth.

Curated Network

Early-stage founders often face steep learning curves across critical areas like regulation, reimbursement, and commercialization. Our deep industry connections bridge that gap—providing direct access to investors, regulatory advisors, reimbursement strategists, and seasoned experts who help transform inexperience into execution.

Strategic Investment

In a tightening capital environment—where VC fundraising is at its slowest pace since 2019 and life science deal volume continues to decline—strategic investment is more critical than ever. We provide targeted funding and expert guidance, giving startups the capital and focused support they need to scale sustainably and stand out in a constrained market.

Active Engagement

With each month that passes without investment, a company's probability of success declines. That’s why we actively engage with founders to understand their unique needs and ensure every step, from mentorship to programming, is aligned for growth.

Curated Network

Early-stage founders often face steep learning curves across critical areas like regulation, reimbursement, and commercialization. Our deep industry connections bridge that gap—providing direct access to investors, regulatory advisors, reimbursement strategists, and seasoned experts who help transform inexperience into execution.

Strategic Investment

In a tightening capital environment—where VC fundraising is at its slowest pace since 2019 and life science deal volume continues to decline—strategic investment is more critical than ever. We provide targeted funding and expert guidance, giving startups the capital and focused support they need to scale sustainably and stand out in a constrained market.

Navigating the Valley of Death

A highly specialized blend of human resources, funding, and domain expertise is essential for life science startups to succeed. Limited access to these critical items, however, remains the primary reason why 90% of life science startups fail to cross the “valley of death.”

Howarth, J. (2023, November 3). Startup failure rate statistics (2024). Exploding Topics. Retrieved from https://explodingtopics.com/blog/startup-failure-stats

Active
Engagement

Curated
Network

Strategic
Investment

Valley-Death-Background

Market Validation

Access to Talent

Regulatory Hurdles

Clinical Uncertainty

Funding Gap

Life Science Valley of Death

Failure

Success

The Minds Behind LifeX Our Team

The LifeX team brings together program builders, connectors, strategists, and ecosystem builders focused on one goal:

Helping Life Science Startups Succeed

What we bring isn’t a roster of in-house experts across every domain a founder might need. It’s the judgment to know what a company needs at each stage, the relationships to go get it, and the operational rigor to make it happen.

Jerry-Vardzel-Headshot

Gerald Vardzel

President & CEO

Kelly-Collier-Headshot

Kelly Collier

Director of Ecosystem Development

Michael-Young-Headshot

Michael Young

VP Operations, Finance & Administration

Geneva-Masak-Headshot

Geneva Masak, PhD

Launchpad Program Manager

Megan-Butler-Headshot

Megan Butler

Program Manager

Join LifeX Build What's Next

Wherever you are in your startup journey, LifeX can help you take the next step. Connect with us to explore how we can support your path to commercialization.

Testimonials LifeX in Action

Made Possible By Our Supporters & Partners

Jerry-Vardzel-Headshot

Gerald Vardzel

President & CEO

Gerald Vardzel is a seasoned healthcare executive with over two decades of leadership experience spanning early-stage startups to Fortune 500 companies. As President and CEO of LifeX, he leads a venture platform dedicated to accelerating the commercialization of life sciences innovations by providing strategic guidance, operational support, and access to capital for emerging healthtech and biotech ventures.

Gerald brings deep expertise in developing and executing go-to-market strategies across the healthcare and life sciences sectors, including equity financing, M&A, market intelligence, and new market development. He has successfully launched technologies through both CLIA and FDA regulatory pathways, building delivery chains that span from scientific discovery to clinical adoption. His experience includes designing sales and marketing programs that not only drive market expansion but also enhance client satisfaction, streamline operations, and improve profitability.

Throughout his career, Gerald has played a pivotal role in helping innovation-driven companies navigate the complex commercialization landscape, particularly at the intersection of science, business, and regulatory strategy.

Kelly-Collier-Headshot

Kelly Collier

Director of Ecosystem Development

Kelly has spent the past 15 years immersed in Pittsburgh’s healthcare innovation ecosystem as an entrepreneur, investor, and corporate innovator. She began as the founder and CEO of a medical device startup spun out of Carnegie Mellon, later leading new product development and R&D at the medical equipment company that acquired her venture. At UPMC Enterprises—the innovation and corporate VC arm of UPMC—she contributed to investment diligence and the rollout of IT solutions across the health system.

Currently, Kelly leads strategy and execution at LifeX, overseeing programs and services that support the launch and growth of clinically impactful, commercially viable life science startups. She is passionate about building a thriving startup community by connecting founders with expertise, industry collaborators, and pathways for global reach.

Michael-Young-Headshot

Michael Young

Vice President Operations, Finance & Administration

Michael currently oversees Operations, Finance, and Strategic Analysis across all LifeX entities and also serves as Treasurer. A seasoned finance executive with over 20 years of experience, he brings deep expertise in financial management, reporting, auditing, strategic planning, forecast modeling, and investment analysis.

His career spans multiple industries—including healthcare, energy, logistics, and software—where he has led high-impact initiatives to optimize financial performance and support organizational growth.

Michael holds a Bachelor of Business Administration in Accounting from Niagara University and a Master of Business Administration in Finance from Le Moyne College. He brings a strong combination of strategic insight and operational rigor to the LifeX leadership team.

Geneva-Masak-Headshot

Geneva Masak, PhD

Launchpad Program Manager

Geneva Masak, PhD, is a scientist-turned-venture-builder with a passion for translating cutting-edge science into real-world impact. With a strong foundation in research and an entrepreneurial mindset, she thrives on helping big scientific ideas navigate the challenges of early-stage commercialization.

Geneva earned her PhD in Integrative Systems Biology from the University of Pittsburgh, where her research focused on the biomechanics of tissue and cell movements—work that sharpened her analytical skills and deepened her understanding of complex biological systems.

At LifeX, Geneva brings a critical eye for scientific feasibility and a strong interest in the business models, regulatory strategies, and market dynamics that drive venture success. Her ability to bridge the gap between bench science and business execution makes her a valuable partner to emerging founders.

Outside the lab and startup world, Geneva channels her energy into parkour, embracing both its physical and mental challenges, and finds grounding through her lifelong love of horses.

Megan-Butler-Headshot

Megan Butler

Program Manager

Megan Butler is a Program Manager at LifeX, where she leads the LifeX Accelerator, a three-month virtual program for high-potential life science and healthcare ventures. She brings extensive experience in Pittsburgh’s entrepreneurial ecosystem, having held roles at Venture For America and the Jewish Healthcare Foundation. A Pittsburgh resident for over a decade, Megan holds a Bachelor’s in Policy & Management and Decision Science and a Master’s in Healthcare Policy & Management from Carnegie Mellon University.